Alvotech Attacks AbbVie Over Adalimumab

Launches US Legal Challenge Over Humira Patent ‘Monopoly’

 
• By Dave Wallace

Alvotech has launched a US legal challenge over intellectual property around AbbVie’s Humira, claiming that the company enjoys a “wrongful monopoly” on the top-selling arthritis treatment for which the biosimilars company is developing a high-concentration adalimumab rival.

Danger Minefield Sign
Alvotech has cited the “minefield of IP” around Humira • Source: Alamy

More from Biosimilars

More from Products